Remember Me
Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Pentier, Johanne
Languages: English
Types: Doctoral thesis
Subjects: QH426, R1
Human T-cells play a major role in controlling and clearing Mycobacterial infections. The adaptive immune system deploys a complex network of specialised T-cell subsets in order to tailor an optimum immune response. Two categories of T-cells have been described that are characterised by the ligands they recognise: “conventional” T-cells (polymorphic, HLA-restricted, peptide-specific) and “unconventional” T-cells (non-polymorphic, restricted by HLA-like molecules, non-peptide-specific). Both T-cell categories were shown to be important for the elimination of cells infected with Mycobacterium tuberculosis (M. tuberculosis) and their role, specificities and functionalities are under active investigation in order to develop optimum vaccination strategies. A large interest in unconventional T-cells, such as MR1-restricted MAITs or CD1-specific T-cells, and their role in mycobacterial infections has recently arisen. I initiated my studies by dissecting T-cell responses generated during direct ex vivo boosting of PBMCs with antigen presenting cells that had phagocytosed Mycobacterium smegmatis (M. smegmatis). M. smegmatis is a non-pathogenic bacterium and is mainly eliminated by the innate immune system. However, T-cells might respond to M. smegmatis antigens and therefore play a role in clearing the pathogen. Using polychromatic flow cytometry, I successfully identified major CD3+ conventional and unconventional M. smegmatis-specific T-cell populations and evaluated their respective frequencies and distribution. The identification of a significant frequency of M. smegmatis-specific unconventional MAITs pushed me to further analyse the specificity of this interesting T-cell subset. At the time of my studies, the ligand(s) presented by MR1 to MAITs were still undiscovered. However, structural models of MR1 groove moiety provided evidences that MR1 could potentially present peptides to MAITs. Therefore, I attempted to identify the molecular and cellular mechanisms by which an M. tuberculosis-specific MAIT clone recognises peptide loaded on MR1 and to refold this MHC-like protein. Vaccination strategies have been mainly focusing on targeting CD8 T-cells, known to be essential for the host defence against mycobacterial infections. Therefore a huge effort is made to discover new immunodominant mycobacterial epitopes. Collaborators isolated the HLA-A*0201-restricted D454 T-cell clone specific to the LLDAHIPQL epitope derived from the highly immunogenic Esx-G protein. The LLDAHIPQL sequence is conserved across mycobacterial species thus offering potential for pan-mycobacterial vaccination. I aimed at proving that D454 TCR binds to HLA-A*0201-LLDAHIPQL. I successfully obtained an HLA-A*0201-LLDAHIPQL crystal structure, the first bacterially-derived HLA-peptide complex, and identified the key mechanisms involved in the molecular recognition of HLA-A*0201-LLDAHIPQL by a conventional TCR.

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok